ClinicalTrials.gg
CompletedNCT03434041Updated Apr 29, 2025Results posted

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

A Phase 3 interventional study of Esketamine 56 mg and Esketamine 84 mg in Depressive Disorder, Treatment-Resistant, sponsored by Janssen Research & Development, LLC. Completed at 30 sites in 2 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-04-29.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant — 4 open to participants now, 4 under way, 2 of them phase 3. Esketamine · Depressive Disorder, Treatment-Resistant.

Enrollment
8th of 18
252 · median 210
Started
2018
the only one that year
Phase 3
11 of 18
2 open now
Registered
9th of 18
by date
Lead sponsor
11 of 18
Janssen Research & Development, LLC

Among the 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant, this one is the 8th largest by enrollment, is the only one that started in 2018, is one of 11 in phase 3, and was the 9th registered.

Depressive Disorder, Treatment-Resistant

448 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

4 of the 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About esketamine

Esketamine: first FDA approval 2019 (SPRAVATO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 114 Depressive Disorder, Treatment-Resistant studies recruiting now, 26 (23%) set no upper age limit and 76 (67%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of switching adult participants with treatment-resistant depression (TRD) from a prior antidepressant treatment (to which they have not responded) to flexibly dosed intranasal esketamine (56 milligram [mg] or 84 mg) plus a newly initiated oral antidepressant compared with switching to a newly initiated oral antidepressant (active comparator) plus intranasal placebo, in improving depressive symptoms. Efficacy will be assessed by the change from baseline in the Montgomery Asberg Depression Rating Scale (MADRS) total score from Day 1 (before randomization) to the end of the 4-week double-blind treatment phase.

03

Conditions studied

  • Depressive Disorder, Treatment-Resistant
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At the start of the screening/prospective observational phase, participant must meet the -fifth edition (DSM-5) diagnostic criteria for recurrent major depressive disorder (MDD) or single-episode MDD, without psychotic features, based upon clinical assessment and confirmed by the Mini-International Neuropsychiatric Interview (mental status questionnaire) (MINI)
  • At the start of the screening/prospective observational phase, participant must have had non-response (less than or equal to [\<=] 25 percent [%] improvement) to >=1 but \<=5 (if current episode is greater than (>) 2 years or not definable, upper limit is applicable to only the last 2 years) oral antidepressant treatments in the current episode of depression, assessed using the Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and confirmed by documented records (for example, medical/ pharmacy/prescription records or letter from a treating physician). In addition, the participant is taking a different oral antidepressant treatment (on the MGH-ATRQ) for at least the previous 2 weeks at or above the minimum therapeutic dose
  • The participant's current major depressive episode, depression symptom severity (Week 1 Montgomery-Asberg Depression Rating Scale [MADRS] total score >=28 required), and antidepressant treatment response in the current depressive episode, must be confirmed using a Clinical-Validation Inventory for Study Admission (C-VISA)
  • Participant must be medically stable on the basis of physical examination, medical history, vital signs (including blood pressure), pulse oximetry, and 12-lead (ECG) performed in the screening/prospective observational phase. If there are any abnormalities that are not specified in the inclusion and exclusion criteria, they must be consistent with the underlying illness in the study population. This determination must be recorded in the participant's source documents and initialed or signed by the investigator
  • Participant must be medically stable on the basis of clinical laboratory tests performed in the screening/prospective observational phase. If the results of the serum chemistry panel, hematology, or urinalysis are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not or to be appropriate and reasonable for the population under study. This determination must be recorded in the participant's source documents and initialed or signed by the investigator

Exclusion criteria

Exclusion Criteria:

  • The participant's depressive symptoms have previously demonstrated non-response to:

    1. Esketamine or ketamine in the current major depressive episode per clinical judgment, or
    2. All of the oral antidepressant treatment options available in the respective country for the double-blind phase (that is, duloxetine, escitalopram, sertraline, and venlafaxine XR) in the current major depressive episode (based on MGH-ATRQ), or
    3. An adequate course of treatment with electroconvulsive therapy (ECT) in the current major depressive episode, defined as at least 7 treatments with unilateral/bilateral ECT
  • Participant has received vagal nerve stimulation (VNS) or has received deep brain stimulation (DBS) in the current episode of depression
  • Participant has a current or prior diagnosis of a psychotic disorder or MDD with psychotic features, bipolar or related disorders (confirmed by the MINI), obsessive compulsive disorder (current only), intellectual disability (DSM-5 diagnostic codes 315.8, 317, 318.0, 318.1, 318.2 and 319), autism spectrum disorder, borderline personality disorder, antisocial personality disorder, histrionic personality disorder, or narcissistic personality disorder
  • Participant has homicidal ideation/intent, per the investigator's clinical judgment, or has suicidal ideation with some intent to act within 6 months prior to the start of the screening/prospective observational phase, per the investigator's clinical judgment or based on the Columbia Suicide Severity Rating Scale (C-SSRS), corresponding to a response of "Yes" on Item 4 (active suicidal ideation with some intent to act, without specific plan) or Item 5 (active suicidal ideation with specific plan and intent) for suicidal ideation on the C-SSRS, or a history of suicidal behavior within the past year prior to the start of the screening/prospective observational phase. Participants reporting suicidal ideation with intent to act or suicidal behavior prior to the start of the double-blind treatment phase should be excluded
  • Participant has a history of moderate or severe substance or alcohol use disorder according to DSM-5 criteria, except nicotine or caffeine, within 6 months before the start of screening/prospective observational phase a. A history (lifetime) of ketamine, phencyclidine (PCP), lysergic acid diethylamide (LSD), or 3, 4-methylenedioxy-methamphetamine (MDMA) hallucinogen-related use disorder is exclusionary
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
252 participants (actual)

Study arms

  • Experimental
    Intranasal Esketamine plus Oral Antidepressant

    Eligible participants will self-administer esketamine (56 mg or 84 mg) intranasally twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Treatment Phase. All participants will start at a dose of 56 milligram (mg) on Day 1. The dose may be increased to 84 mg or maintained at 56 mg per investigator's discretion. In addition, participants will simultaneously initiate a new, open-label 1 of 4 oral antidepressant medications (duloxetine, escitalopram, sertraline, or venlafaxine extended release \[XR\]) on Day 1 that will be continued for the duration of the 4-week Double-Blind Treatment Phase.

    Drug: Esketamine 56 mg · Drug: Esketamine 84 mg · Drug: Duloxetine (Oral Antidepressant) · Drug: Escitalopram (Oral Antidepressant) · Drug: Sertraline (Oral Antidepressant) · Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant)

  • Active comparator
    Oral Antidepressant plus Intranasal Placebo

    Eligible Participants will self-administer matching placebo intranasally twice per week for 4 weeks in Double-Blind Treatment Phase. In addition, participants will simultaneously initiate a new, open-label oral antidepressant medications (duloxetine, escitalopram, sertraline, or venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Treatment Phase.

    Drug: Placebo · Drug: Duloxetine (Oral Antidepressant) · Drug: Escitalopram (Oral Antidepressant) · Drug: Sertraline (Oral Antidepressant) · Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant)

Interventions

  • Participants will self-administer 56 mg of esketamine as intranasal spray.

  • Participants will self-administer 84 mg of esketamine as intranasal spray.

  • DrugPlacebo

    Participants will self-administer matching placebo as intranasal spray.

  • Duloxetine can be selected as the oral antidepressant medication based on investigator's discretion. The minimum therapeutic dose is 60 milligram per day (mg/day).

  • Escitalopram can be selected as the oral antidepressant medication based on investigator's discretion. Escitalopram will be started at a dose of 10 mg/day and up-titrated to a maximum dose of 20 mg/day.

  • Sertraline can be selected as the oral antidepressant medication based on investigator's discretion. Sertraline will be started at a dose of 50 mg/day and up-titrated to a maximum dose of 200 mg/day.

  • Venlafaxine XR can be selected as the oral antidepressant medication based on investigator's discretion. Venlafaxine XR will be started at a dose of 75 mg/day and up-titrated to a maximum dose of 225 mg/day.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score to the End of Double-blind Treatment Phase (Day 28)

    The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score range of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement.

    Time frame: Baseline up to end of the double-blind treatment phase (Day 28)

Secondary outcomes

  1. Change From Baseline in Depressive Symptoms as Measured by the MADRS Total Score to 24 Hours Post First Dose (Day 2)

    The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score range of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement.

    Time frame: Baseline (Day 1: predose) to 24 hours post first dose (Day 2)

  2. Change From Baseline in Sheehan Disability Scale (SDS) Total Score to the End of Double-blind Treatment Phase (Day 28)

    The SDS is a subject-reported outcome measure that consists of a 5-item questionnaire which has been widely used and accepted for assessment of functional impairment and associated disability. The first three items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a 0-10 rating scale. The score for the first three items are summed to create a total score of 0-30, where a higher score indicates greater impairment. It also has one item on days lost from school or work and one item on days when underproductive.

    Time frame: Baseline up to end of the double-blind treatment phase (Day 28)

  3. Percentage of Participants With Onset of Clinical Response

    Onset of clinical response is defined as greater than or equal to (\>=) 50 percent (%) improvement from baseline in MADRS total score with onset by Day 2 that was maintained through Day 28. The MADRS scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score range of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement.

    Time frame: Day 2 up to Day 28

  4. Percentage of Responders at the End of Double-blind Treatment Phase (Day 28)

    Percentage of responders at the end of double-blind treatment phase (Day 28) were assessed. A participant was defined as a responder at a given time point if the percent improvement from baseline in MADRS total score is at least 50%. The MADRS scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score range of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement.

    Time frame: Day 28

  5. Percentage of Participants in Remission at the End of Double-blind Treatment Phase (Day 28)

    Percentage of participants in remission at the end of double-blind treatment phase (Day 28) were assessed. A participant was considered as a remitter if participant had a MADRS total score of less than or equal to \[\<=\] 12 at a visit. MADRS scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score range of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement.

    Time frame: Day 28

  6. Percentage of Participants With Sustained Remission

    Sustained remission is defined as the first occurrence of remission (MADRS Total score \<=12) that was maintained through the Day 28 assessment with one excursion prior to Day 28. The MADRS scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score range of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement.

    Time frame: Up to Day 28

  7. Change From Baseline in Clinical Global Impression Severity (CGI-S) Scale Score up to the Endpoint (Double-blind Treatment Phase [Day 28])

    The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S evaluates the severity of psychopathology on a scale of 1 to 7. Considering total clinical experience, a participant is assessed on severity of mental illness at the time of rating according to: 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. The CGI-S permits a global evaluation of the participant's condition at a given time. Negative change in score indicates improvement. The last post-baseline observation during the double-blind phase was carried forward as Endpoint.

    Time frame: Baseline up to Double-blind Endpoint (Day 28)

  8. Change From Baseline in Generalized Anxiety Disorder 7-item (GAD-7) Scale Score up to the Endpoint (Double-blind Treatment Phase [Day 28])

    The GAD-7 is a brief and validated 7-item self-reported assessment of overall anxiety. Participants respond to each item using a 4 point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15-21). The last post-baseline observation during the double-blind phase was carried forward as the "Endpoint".

    Time frame: Baseline up to Endpoint (double-blind treatment phase [Day 28])

  9. Change From Baseline in Participant-Reported Health-Related Quality of Life as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) Score up to the Endpoint (Double-blind Treatment Phase [Day 28]): Health Status Index

    The EQ-5D-5L is a standardized 2-part instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. It essentially consists of the EQ-5D-5L descriptive system and the EQ Visual Analogue Scale (EQ-VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions is divided into 5 levels of perceived problems (Level 1 indicating no problem, Level 2 indicating slight problems, Level 3 indicating moderate problems, Level 4 indicating severe problems, and Level 5 indicating extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a HSI. Health Status Index ranges from -0.148 to 0.949, and is anchored at 0 (dead) and 1 (full health), a lower score indicates worse health.

    Time frame: Baseline up to Double-blind Endpoint (Day 28)

  10. Change From Baseline in Participant-Reported Health Status as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) Score up to the Endpoint (Double-blind Treatment Phase [Day 28]): Visual Analogue Scale (VAS)

    The EQ-5D-5L is a standardized 2-part instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. It essentially consists of the EQ-5D-5L descriptive system and the EQ-VAS. EQ-VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Positive change in score indicates improvement.

    Time frame: Baseline up to Double-blind Endpoint (Day 28)

  11. Change From Baseline in Participant-Reported Health Status as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to the Endpoint (Double-blind Treatment Phase [Day 28]): Sum Score

    EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a Health Status Index (HSI). HSI ranges from -0.148 to 0.949 and is anchored at 0 (health state value equal to dead) and 1 (full health). EQ-VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) \*5. Higher score indicates worst health state.

    Time frame: Baseline up to Double-blind Endpoint (Day 28)

07

Results

Posted May 24, 2022
Limitations and caveats
As esketamine has known transient dissociative effects that are difficult to blind, these specific treatment-emergent events could have biased the staff who provided and observed the dosing. Therefore, to ensure an unbiased efficacy evaluation, independent, remote (by telephone), blinded MADRS raters were used to assess the treatment response.

Participant flow

Double Blind Treatment Phase (4 Weeks)
Participant flow — Double Blind Treatment Phase (4 Weeks)
MilestoneIntranasal Esketamine + Oral Antidepressant (AD)Intranasal Placebo + Oral AD
Started126126
Full analysis set124126
Completed108106
Not completed1820
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject21
Withdrew: Lack of efficacy314
Withdrew: Adverse event72
Withdrew: Death10
Withdrew: Covid-19 related22
Withdrew: Non-compliance with study drug01
Withdrew: Other20
Follow-up Phase (Up to 8 Weeks)
Participant flow — Follow-up Phase (Up to 8 Weeks)
MilestoneIntranasal Esketamine + Oral Antidepressant (AD)Intranasal Placebo + Oral AD
Started106103
Completed99100
Not completed73
Withdrew: Withdrawal by subject43
Withdrew: Adverse event20
Withdrew: Investigator decision to discontinue follow-up and proceed to 54135419trd3008 (nct02782104)10

Outcome measures

PrimaryChange From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score to the End of Double-blind Treatment Phase (Day 28)

The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score range of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement.

Time frame:
Baseline up to end of the double-blind treatment phase (Day 28)
Reported as:
Mean · Units on a Scale
Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score to the End of Double-blind Treatment Phase (Day 28)
Units on a ScaleIntranasal Esketamine + Oral Antidepressant (AD)Intranasal Placebo + Oral AD
Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score to the End of Double-blind Treatment Phase (Day 28)-10.1 ± 10.80-8.1 ± 10.26
Statistical analysis
  • Intranasal Esketamine + Oral Antidepressant (AD) · Mixed-effects Model for Repeated Measure · p = 0.123 (2-sided) · Difference of least square (ls) means: -2.0 · 95% CI -4.64 to 0.55
SecondaryChange From Baseline in Depressive Symptoms as Measured by the MADRS Total Score to 24 Hours Post First Dose (Day 2)

The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score range of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement.

Time frame:
Baseline (Day 1: predose) to 24 hours post first dose (Day 2)
Reported as:
Mean · Units on a Scale
Change From Baseline in Depressive Symptoms as Measured by the MADRS Total Score to 24 Hours Post First Dose (Day 2)
Units on a ScaleIntranasal Esketamine + Oral Antidepressant (AD)Intranasal Placebo + Oral AD
Change From Baseline in Depressive Symptoms as Measured by the MADRS Total Score to 24 Hours Post First Dose (Day 2)-8.0 ± 9.01-4.4 ± 7.66
Statistical analysis
  • Intranasal Esketamine + Oral Antidepressant (AD) · Difference of ls means: -3.3 · 95% CI -5.33 to -1.33
SecondaryChange From Baseline in Sheehan Disability Scale (SDS) Total Score to the End of Double-blind Treatment Phase (Day 28)

The SDS is a subject-reported outcome measure that consists of a 5-item questionnaire which has been widely used and accepted for assessment of functional impairment and associated disability. The first three items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a 0-10 rating scale. The score for the first three items are summed to create a total score of 0-30, where a higher score indicates greater impairment. It also has one item on days lost from school or work and one item on days when underproductive.

Time frame:
Baseline up to end of the double-blind treatment phase (Day 28)
Reported as:
Mean · Units on a Scale
Change From Baseline in Sheehan Disability Scale (SDS) Total Score to the End of Double-blind Treatment Phase (Day 28)
Units on a ScaleIntranasal Esketamine + Oral Antidepressant (AD)Intranasal Placebo + Oral AD
Change From Baseline in Sheehan Disability Scale (SDS) Total Score to the End of Double-blind Treatment Phase (Day 28)-6.3 ± 7.54-5.3 ± 7.03
Statistical analysis
  • Intranasal Esketamine + Oral Antidepressant (AD) · Difference of ls means: -1.0 · 95% CI -2.96 to 0.97
SecondaryPercentage of Participants With Onset of Clinical Response

Onset of clinical response is defined as greater than or equal to (\>=) 50 percent (%) improvement from baseline in MADRS total score with onset by Day 2 that was maintained through Day 28. The MADRS scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score range of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement.

Time frame:
Day 2 up to Day 28
Reported as:
Number · Percentage of participants
Percentage of Participants With Onset of Clinical Response
Percentage of participantsIntranasal Esketamine + Oral Antidepressant (AD)Intranasal Placebo + Oral AD
Percentage of Participants With Onset of Clinical Response6.51.6
SecondaryPercentage of Responders at the End of Double-blind Treatment Phase (Day 28)

Percentage of responders at the end of double-blind treatment phase (Day 28) were assessed. A participant was defined as a responder at a given time point if the percent improvement from baseline in MADRS total score is at least 50%. The MADRS scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score range of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement.

Time frame:
Day 28
Reported as:
Number · Percentage of Responders
Percentage of Responders at the End of Double-blind Treatment Phase (Day 28)
Percentage of RespondersIntranasal Esketamine + Oral Antidepressant (AD)Intranasal Placebo + Oral AD
Percentage of Responders at the End of Double-blind Treatment Phase (Day 28)19.316.0
SecondaryPercentage of Participants in Remission at the End of Double-blind Treatment Phase (Day 28)

Percentage of participants in remission at the end of double-blind treatment phase (Day 28) were assessed. A participant was considered as a remitter if participant had a MADRS total score of less than or equal to \[\<=\] 12 at a visit. MADRS scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score range of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement.

Time frame:
Day 28
Reported as:
Number · Percentage of Participants
Percentage of Participants in Remission at the End of Double-blind Treatment Phase (Day 28)
Percentage of ParticipantsIntranasal Esketamine + Oral Antidepressant (AD)Intranasal Placebo + Oral AD
Percentage of Participants in Remission at the End of Double-blind Treatment Phase (Day 28)12.810.4
SecondaryPercentage of Participants With Sustained Remission

Sustained remission is defined as the first occurrence of remission (MADRS Total score \<=12) that was maintained through the Day 28 assessment with one excursion prior to Day 28. The MADRS scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score range of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement.

Time frame:
Up to Day 28
Reported as:
Number · Percentage of Participants
Percentage of Participants With Sustained Remission
Percentage of ParticipantsIntranasal Esketamine + Oral Antidepressant (AD)Intranasal Placebo + Oral AD
Percentage of Participants With Sustained Remission5.66.3
SecondaryChange From Baseline in Clinical Global Impression Severity (CGI-S) Scale Score up to the Endpoint (Double-blind Treatment Phase [Day 28])

The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S evaluates the severity of psychopathology on a scale of 1 to 7. Considering total clinical experience, a participant is assessed on severity of mental illness at the time of rating according to: 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. The CGI-S permits a global evaluation of the participant's condition at a given time. Negative change in score indicates improvement. The last post-baseline observation during the double-blind phase was carried forward as Endpoint.

Time frame:
Baseline up to Double-blind Endpoint (Day 28)
Reported as:
Median · Units on a Scale
Change From Baseline in Clinical Global Impression Severity (CGI-S) Scale Score up to the Endpoint (Double-blind Treatment Phase [Day 28])
Units on a ScaleIntranasal Esketamine + Oral Antidepressant (AD)Intranasal Placebo + Oral AD
Change From Baseline in Clinical Global Impression Severity (CGI-S) Scale Score up to the Endpoint (Double-blind Treatment Phase [Day 28])-1.0 (-5 to 1)-1.0 (-5 to 1)
SecondaryChange From Baseline in Generalized Anxiety Disorder 7-item (GAD-7) Scale Score up to the Endpoint (Double-blind Treatment Phase [Day 28])

The GAD-7 is a brief and validated 7-item self-reported assessment of overall anxiety. Participants respond to each item using a 4 point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15-21). The last post-baseline observation during the double-blind phase was carried forward as the "Endpoint".

Time frame:
Baseline up to Endpoint (double-blind treatment phase [Day 28])
Reported as:
Mean · Units on a Scale
Change From Baseline in Generalized Anxiety Disorder 7-item (GAD-7) Scale Score up to the Endpoint (Double-blind Treatment Phase [Day 28])
Units on a ScaleIntranasal Esketamine + Oral Antidepressant (AD)Intranasal Placebo + Oral AD
Change From Baseline in Generalized Anxiety Disorder 7-item (GAD-7) Scale Score up to the Endpoint (Double-blind Treatment Phase [Day 28])-4.3 ± 5.65-2.9 ± 5.28
SecondaryChange From Baseline in Participant-Reported Health-Related Quality of Life as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) Score up to the Endpoint (Double-blind Treatment Phase [Day 28]): Health Status Index

The EQ-5D-5L is a standardized 2-part instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. It essentially consists of the EQ-5D-5L descriptive system and the EQ Visual Analogue Scale (EQ-VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions is divided into 5 levels of perceived problems (Level 1 indicating no problem, Level 2 indicating slight problems, Level 3 indicating moderate problems, Level 4 indicating severe problems, and Level 5 indicating extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a HSI. Health Status Index ranges from -0.148 to 0.949, and is anchored at 0 (dead) and 1 (full health), a lower score indicates worse health.

Time frame:
Baseline up to Double-blind Endpoint (Day 28)
Reported as:
Mean · Units on a Scale
Change From Baseline in Participant-Reported Health-Related Quality of Life as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) Score up to the Endpoint (Double-blind Treatment Phase [Day 28]): Health Status Index
Units on a ScaleIntranasal Esketamine + Oral Antidepressant (AD)Intranasal Placebo + Oral AD
Change From Baseline in Participant-Reported Health-Related Quality of Life as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) Score up to the Endpoint (Double-blind Treatment Phase [Day 28]): Health Status Index0.152 ± 0.22940.103 ± 0.2084
SecondaryChange From Baseline in Participant-Reported Health Status as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) Score up to the Endpoint (Double-blind Treatment Phase [Day 28]): Visual Analogue Scale (VAS)

The EQ-5D-5L is a standardized 2-part instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. It essentially consists of the EQ-5D-5L descriptive system and the EQ-VAS. EQ-VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Positive change in score indicates improvement.

Time frame:
Baseline up to Double-blind Endpoint (Day 28)
Reported as:
Mean · Units on a Scale
Change From Baseline in Participant-Reported Health Status as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) Score up to the Endpoint (Double-blind Treatment Phase [Day 28]): Visual Analogue Scale (VAS)
Units on a ScaleIntranasal Esketamine + Oral Antidepressant (AD)Intranasal Placebo + Oral AD
Change From Baseline in Participant-Reported Health Status as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) Score up to the Endpoint (Double-blind Treatment Phase [Day 28]): Visual Analogue Scale (VAS)16.7 ± 20.4711.9 ± 25.21
SecondaryChange From Baseline in Participant-Reported Health Status as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to the Endpoint (Double-blind Treatment Phase [Day 28]): Sum Score

EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a Health Status Index (HSI). HSI ranges from -0.148 to 0.949 and is anchored at 0 (health state value equal to dead) and 1 (full health). EQ-VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) \*5. Higher score indicates worst health state.

Time frame:
Baseline up to Double-blind Endpoint (Day 28)
Reported as:
Mean · Units on a Scale
Change From Baseline in Participant-Reported Health Status as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to the Endpoint (Double-blind Treatment Phase [Day 28]): Sum Score
Units on a ScaleIntranasal Esketamine + Oral Antidepressant (AD)Intranasal Placebo + Oral AD
Change From Baseline in Participant-Reported Health Status as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to the Endpoint (Double-blind Treatment Phase [Day 28]): Sum Score-13.4 ± 18.83-9.5 ± 16.95

Adverse events

Collected over Up to 16 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-blind: Intranasal Esketamine+ Oral Antidepressant (AD)1/126 (0.8%)3/126 (2.4%)118/126 (93.7%)
Double-blind: Oral AD + Intranasal Placebo0/126 (0%)3/126 (2.4%)61/126 (48.4%)
Follow-up: Intranasal Esketamine+ Oral AD0/106 (0%)2/106 (1.9%)10/106 (9.4%)
Follow-up: Oral AD + Intranasal Placebo0/103 (0%)2/103 (1.9%)13/103 (12.6%)
Most frequent serious events
Most frequent serious events
EventDouble-blind: Intranasal Esketamine+ Oral Antidepressant (AD)Double-blind: Oral AD + Intranasal PlaceboFollow-up: Intranasal Esketamine+ Oral ADFollow-up: Oral AD + Intranasal Placebo
DepressionPsychiatric disorders1/1263/1261/1061/103
Cholecystitis AcuteHepatobiliary disorders0/1260/1260/1061/103
Suicide AttemptPsychiatric disorders1/1260/1261/1060/103
Completed SuicidePsychiatric disorders1/1260/1260/1060/103
Most frequent other events
Showing 10 of 20
Most frequent other events
EventDouble-blind: Intranasal Esketamine+ Oral Antidepressant (AD)Double-blind: Oral AD + Intranasal PlaceboFollow-up: Intranasal Esketamine+ Oral ADFollow-up: Oral AD + Intranasal Placebo
DizzinessNervous system disorders97/12625/1260/1061/103
DissociationPsychiatric disorders75/1268/1260/1061/103
NauseaGastrointestinal disorders53/12617/1260/1063/103
Blood Pressure IncreasedInvestigations38/12613/1261/1062/103
HypoaesthesiaNervous system disorders25/1261/1260/1060/103
Vision BlurredEye disorders23/1261/1260/1060/103
VomitingGastrointestinal disorders23/1262/1260/1062/103
SomnolenceNervous system disorders20/12611/1260/1061/103
HeadacheNervous system disorders16/12614/1263/1060/103
DysgeusiaNervous system disorders14/1266/1260/1061/103

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Intranasal Esketamine + Oral Antidepressant (AD)Intranasal Placebo + Oral ADTotal
<=18 years000
Between 18 and 65 years126126252
>=65 years000
Age, Continuous
Age, Continuous(years)Intranasal Esketamine + Oral Antidepressant (AD)Intranasal Placebo + Oral ADTotal
Mean36.8 ± 11.9537.8 ± 12.3637.3 ± 12.14
Sex: Female, Male
Sex: Female, Male(Participants)Intranasal Esketamine + Oral Antidepressant (AD)Intranasal Placebo + Oral ADTotal
Female5855113
Male6871139
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Intranasal Esketamine + Oral Antidepressant (AD)Intranasal Placebo + Oral ADTotal
Hispanic or Latino213
Not Hispanic or Latino121124245
Unknown or Not Reported314
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Intranasal Esketamine + Oral Antidepressant (AD)Intranasal Placebo + Oral ADTotal
American Indian or Alaska Native000
Asian112112224
Native Hawaiian or Other Pacific Islander000
Black or African American145
White12921
More than one race101
Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(Participants)Intranasal Esketamine + Oral Antidepressant (AD)Intranasal Placebo + Oral ADTotal
CHINA112112224
UNITED STATES141428
08

Study locations

30 sites
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • Biomedical Research Foundation of Northwest Louisiana
    Shreveport, Louisiana 71104-2136, United States
  • CBH Health
    Gaithersburg, Maryland 20877, United States
  • Adams Clinical
    Watertown, Massachusetts 02472, United States
  • The Medical Research Network, LLC
    New York, New York 10128, United States
  • IPS Research Company
    Oklahoma City, Oklahoma 73106, United States
  • Beijing Anding Hospital of Capital Medical University
    Beijing, 100088, China
  • Beijing HuiLong Guan Hospital
    Beijing, 100096, China
  • Peking University Sixth Hospital
    Beijing, 100191, China
  • The Second People's Hospital of Hunan Province / Brian Hospital of Hunan Province
    Changsha, 410007, China
  • The second Xiangya Hospital of Central South University
    Changsha, 410011, China
  • West China Hospital Sichuan University
    Chengdu, 610041, China
  • Chongqing Mental Health Center
    Chongqing, 401147, China
  • the 3rd Affiliated Hospital,Sun Yansen University
    Guangzhou, 510000, China
  • Guangdong Provincial People's Hospital
    Guangzhou, 510100, China
  • Hangzhou Seventh People's Hospital
    Hangzhou, 310000, China
  • First Hospital, Zhejiang University Medical College
    Hangzhou, 310003, China
  • The Second Affiliated Hospital of Zhejiang University
    Hangzhou, 310009, China
  • Huzhou third people's Hospital
    Hu Zhou, 313000, China
  • First Affiliated Hospital of Kunming Medical Unversity
    Kunming City, 650032, China
  • Nanjing Brain Hospital Affilicated to Nanjing Medical University
    Nanjing, 210000, China
  • The First Hospital of Hebei Medical University
    Shijiazhuang, 050031, China
  • Tianjin Anding Hospital
    Tianjin, 300222, China
  • Urumqi fourth Hospital
    Urumqi, 830000, China
  • The first affiliated hospital of Xinjiang medical university
    Urumqi, 830054, China
  • Renmin Hospital of Wuhan University
    Wuhan, 430060, China
  • The First Affiliated Hospital of Xian Jiaotong University
    Xi'an, 710061, China
  • Xi'an Mental Health Center
    Xi'an, 710061, China
  • Xiamen Xianyue Hospital
    Xia Men, 361012, China
  • The First Affiliated Hospital of Zhengzhou University
    Zheng Zhou, 450052, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Apr 2021, 34 months.

Results were first posted in May 2022, 1 year 1 month after primary completion.

Of 24 phase 3 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 34 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2018
First posted
Feb 15, 2018
StartActual
May 25, 2018
Primary completionActual
Apr 13, 2021
CompletionActual
Apr 13, 2021
Results first posted
May 24, 2022
Last update
Apr 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03434041
Responsible party
Sponsor
First posted
Feb 15, 2018
Start date
May 25, 2018
Primary completion
Apr 13, 2021
Completion
Apr 13, 2021
Results posted
May 24, 2022
Last update
Apr 29, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esketamine

Start the discussion